Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL2L1 | Q07817 | 1/20 | 0.39 |
| ▸ | BAD | Q92934 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.33 |
| ▸ | CA2 | P00918 | 2/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
| ▸ | LPL | P06858 | 1/20 | 0.33 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.33 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3737580 | 0.83 | — | — | |
| SCHEMBL4035335 | 0.83 | POLB (0.46) | S1PR1POLBGAAMEN1KMT2A | |
| Water SCHEMBL31152424 | 0.80 | POLB (0.43) | S1PR1POLBGAAMEN1KMT2A | |
| SCHEMBL197346 | 0.76 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL12562793 | 0.76 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL10300262 | 0.76 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL10337645 | 0.76 | BCL2L1 (0.55) | BCL2L1BADMAOBNPC1RAB9A | |
| SCHEMBL3087036 | 0.74 | CYP3A4 (0.58) | NPC1RAB9APOLBCA1CA2 | |
| SCHEMBL12132107 | 0.74 | RAB9A (0.44) | NPC1RAB9APOLBACHEGAA | |
| SCHEMBL3477590 | 0.74 | CYP1A2 (0.48) | MAOBNPC1RAB9APOLBMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE41425-E1 | used for the treatment of affective disorders or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems, such as schizophrenia | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-RE41425-E1 | used for the treatment of affective disorders or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems, such as schizophrenia | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-RE41425-E1 | used for the treatment of affective disorders or diseases of the central nervous system caused by disturbances in either the dopaminergic or serotinergic systems, such as schizophrenia | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2010-07-06 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-7432269-B2 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2008-10-07 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | CAPET MARC | 2008-07-10 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | BIOPROJET (FR) | 2006-04-27 | — | — | US | disclosed |
| EP-0908458-B1 | Substituted pyridylmethylpiperazine and piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INT RES (NL) | 2006-01-25 | — | — | EP | disclosed |
| US-6090812-A | THERAPY FOR PSYCHOLOGICAL, CENTRAL NERVOUS SYSTEM DISORDERS | DUPHAR INTERNATIONAL RESEARCH B.V. (NL) | 2000-07-18 | — | — | US | disclosed |
| EP-0908458-A1 | Substituted pyridylmethylpiperazine and -piperidine derivatives, their preparation and their use for treating central nervous system (CNS) disorders | DUPHAR INTERNATIONAL RESEARCH B.V (NL) | 1999-04-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080167320-A1 | NOVEL ARYLPIPERAZINE DERIVATIVES | DRD2, HTR2C, DRD3 | BCL2L1 3849/4885BAD 2643/4885MAOB 118/4885 |
| US-20060089364-A1 | Arylpiperaszine derivatives, to the process for the production thereof and to the use thereof as therapeutic agents | CYP4Z1, CYP3A5, CYP1A2 | BCL2L1 4503/4885BAD 2552/4885MAOB 63/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.